GOODWILL AND INTANGIBLE ASSETS

3 Months Ended

Mar. 31, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

The changes in goodwill for the three months ended March 31, 2013 and for the year ended December 31, 2012 are as follows:



	March 31, 2013			December 31, 2012
Balance at beginning of period	$	5,535,848		$	5,795,765
Goodwill acquired during the period	94,339			28,144
Goodwill impairment and write-off associated with sale of business during the period	—			(85,173		)
Reclassification to non-current assets held for sale	—			(218,795		)
(Decrease) increase related to foreign currency translation	(85		)	15,907
Balance at end of period	$	5,630,102		$	5,535,848

Approximately 90% of the Company’s goodwill as of March 31, 2013 and December 31, 2012 was associated with its clinical testing business.

For the three months ended March 31, 2013, goodwill acquired was principally associated with the acquisition of the clinical outreach and anatomic pathology businesses of UMass Memorial Medical Center, which is deductible for tax purposes. This acquisition also included $45.8 million of intangible assets, principally comprised of customer-related intangibles.

For the year ended December 31, 2012, goodwill acquired was principally associated with the acquisition of S.E.D. Medical Laboratories. Approximately $28 million and $19 million, respectively, represented goodwill, which is deductible for tax purposes, and intangible assets, principally comprised of customer-related intangibles.

For the year ended December 31, 2012, goodwill impairment was associated with HemoCue and the write-off of goodwill was associated with the sale of OralDNA, during the fourth quarter of 2012. For further details regarding goodwill included in non-current assets held for sale, see Note 12.

Intangible assets at March 31, 2013 and December 31, 2012 consisted of the following:



	Weighted Average Amortization Period (in Years)	March 31, 2013							December 31, 2012
		Cost		Accumulated Amortization			Net		Cost		Accumulated Amortization			Net
Amortizing intangible assets:
Customer-related intangibles	19	$	611,901	$	(182,085	)	$	429,816	$	566,701	$	(173,516	)	$	393,185
Non-compete agreements	4	38,551		(19,502		)	19,049		38,551		(17,123		)	21,428
Technology	14	131,040		(28,073		)	102,967		131,040		(25,144		)	105,896
Other	8	143,153		(43,041		)	100,112		141,818		(37,634		)	104,184
Total	16	924,645		(272,701		)	651,944		878,110		(253,417		)	624,693

Intangible assets not subject to amortization:
Tradenames		246,200		—			246,200		246,200		—			246,200
In-process research and development		120		—			120		120		—			120
Other		1,159		—			1,159		1,159		—			1,159
Total intangible assets		$	1,172,124	$	(272,701	)	$	899,423	$	1,125,589	$	(253,417	)	$	872,172

Amortization expense related to intangible assets was $19.3 million and $18.8 million for the three months ended March 31, 2013 and 2012, respectively.

The estimated amortization expense related to amortizable intangible assets for each of the five succeeding fiscal years and thereafter as of March 31, 2013 is as follows:



Year Ending December 31,
Remainder of 2013	$	57,786
2014	73,847
2015	62,565
2016	55,855
2017	52,101
2018	45,361
Thereafter	304,429
Total	$	651,944

In December 2012, $219 million of goodwill and $111 million of intangible assets, net were reclassified to non-current assets held for sale in the Consolidated Balance Sheet. For further discussion see Note 12.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References+ Details